Azamian Bobak R. sold $615K of TARS (indirect holdings)

Azamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $61.55 ($61.24–$61.81, $0.62M total) across 2 trades on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Azamian Bobak R.
Published Jun 22, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Neutral
medium confidence
Mentioned
$TARS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSNeutralLow
01

Why it matters

The newest fact is the CEO/Chair’s open-market sale amount, timing, and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh, timestamped insider-selling datapoint, but it does not include any new business or financial guidance information.

03

What to watch

Traders may over-weight insider sales; without changes in guidance/clinical milestones, the filing is mostly a sentiment datapoint.

Relevance 4/10Novelty 5/10Timing: after-hours/filing update (filed 2026-06-22)

Background

The article is an SEC Form 4 insider transaction disclosure for Tarsus Pharmaceuticals, Inc.

Company-level read

Ticker impact

$TARSNeutralMedium confidence
Context

SEC Form 4 shows Tarsus Pharmaceuticals CEO/Chair Azamian Bobak R. sold $615,488 of TARS shares via a 10b5-1 plan on 2026-06-17.

Expected impact

Likely limited near-term impact; any effect should fade unless follow-on selling accelerates.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale by the CEO/Chair, with no accompanying operational or guidance news in the text.

Market effects

Minimal; this is company-specific insider trading with no sector-wide regulatory/clinical catalyst mentioned.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may be mechanically scheduled and not predictive of near-term downside.

Key entities

  • Tarsus Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Azamian Bobak R.

    President/CEO and Board Chair who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.